BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Kynurenine 3-monoxygenase (KMO)

February 5, 2015 8:00 AM UTC

In vitro and rat studies suggest novel KMO inhibitors could help treat HD. Patients with HD have elevated brain levels of quinolinic acid (QA) and 3-hydroxykynurenine (3-HK) - neurotoxic metabolites t...